drugset / Trial / NCT03987295
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Timeline
- Start
- 2019-09-27
- Primary completion
- 2024-06-05
- Completion
- 2024-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latozinemab | Monoclonal antibody | 60 mg/kg | Intravenous |